Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc (NQ: APVO )

1.570 +0.010 (+0.64%)
Streaming Delayed Price Updated: 3:57 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,688
Open 1.610
Bid (Size) 1.530 (25)
Ask (Size) 1.580 (9)
Prev. Close 1.560
Today's Range 1.510 - 1.610
52wk Range 1.530 - 7.200
Shares Outstanding 7,290,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
Via ACCESSWIRE
Overview Of Value Stocks In The Healthcare Sector
 
Via Benzinga

Performance

YTD
-31.44%
-31.44%
1 Month
-13.26%
-13.26%
3 Month
-25.24%
-25.24%
6 Month
-49.68%
-49.68%
1 Year
-65.72%
-65.72%

More News

Read More
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
Via ACCESSWIRE
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Via ACCESSWIRE
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
Via ACCESSWIRE
Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Via Benzinga
Dow Surges Over 250 Points; Weber Shares Spike Higher
Via Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
Via Benzinga
US Stocks Higher; Dow Rises Over 100 Points
Via Benzinga
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.